Molsidomine
Based on 1 publication(s) in Google Scholar
Molsidomine, a nitric oxide (NO) donor, is an orally active vasodilator agent. Molsidomine is a prodrug that can be rapidly metabolized in the liver to its active metabolite, Linsidomine (HY-101200). Molsidomine can be used for the study of angina pectoris, mental disorders and diabetic complications.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.90%
- CAS. Nr.: 25717-80-0
- Formel: C9H14N4O4
- Molecular Weight:242.23
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-B1069R
Molsidomine (Standard)Standard of Molsidomine -
HY-101200
Linsidomine hydrochlorideROS/RNS Inducer -
HY-131123
N-NitrosomorpholineCarcinogenic Agent -
HY-B0821
PymetrozineInsecticide -
HY-B0821R
Pymetrozine (Standard)Insecticide -
HY-101200R
Linsidomine hydrochloride (Standard)ROS/RNS Inducer -
HY-131123R
N-Nitrosomorpholine (Standard)Carcinogenic Agent
Publications Citing Use of MedChemExpress (MCE) Molsidomine
More
Biologische Aktivität
Beschreibung
In Vivo
Molsidomine (1 mg/kg; intraperitoneal injection; single dose) combined with either Clozapine (HY-14539) (0.1 mg/kg; intraperitoneal injection; single dose) or Risperidone (HY-11018) (0.03 mg/kg; intraperitoneal injection; single dose) counteracts the non-spatial recognition memory impairments induced by Apomorphine in rats[1].
Molsidomine (5-10 mg/kg; oral administration; once a day; for 8 weeks) in a Wistar rat model of diabetic neuropathy induced by Streptozotocin (HY-13753) improves the motor coordination, mechanical allodynia, and mechanical hyperalgesia caused by diabetes, increases the nerve conduction velocity, reduces the glycosylated hemoglobin and malondialdehyde levels, increases the content of reduced glutathione in the sciatic nerve, and improves the cellular structure of the sciatic nerve[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats (weighing 250-300 g, 3-month-old) were used in the experiment of schizophrenia-like model induced by Apomorphine[1].
-
Dosage:1 mg/kg, 2 mg/kg, 4 mg/kg
-
Administration:Intraperitoneal injection; single dose
-
Result:Attenuated the inhibitory effect of Apomorphine on rats' spatial recognition and emotional memory abilities.
Alleviated the disrupting effects of apomorphine on rodents' non-spatial recognition memory abilities.
-
Animal Model:Male Wistar rats (weighing about 250-300 g) were used in the diabetic neuropathy model induced by Streptozotocin (52mg/kg i.p.)[2].
-
Dosage:5 mg/kg, 10 mg/kg
-
Administration:Oral administration; once a day; for 8 weeks
-
Result:Significantly improved motor coordination, paw withdrawal threshold, mechanical threshold and nerve conduction velocity.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 25717-80-0
-
Appearance Solid
-
Molecular Weight 242.23
-
Formel C9H14N4O4
-
Color White to off-white
-
SMILES
O=C([N-]C1=C[N+](N2CCOCC2)=NO1)OCC
-
Synonyms
SIN-10; Morsydomine
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]2026 Mar:352:151224. PMID: 41791543
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 100 mg/mL (412.83 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (103.21 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (103.21 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Vartzoka F, et al. The Nitric Oxide (NO) Donor Molsidomine Attenuates Memory Impairments Induced by the D1/D2 Dopaminergic Receptor Agonist Apomorphine in the Rat. Molecules. 2023 Sep 28;28(19):6861. [Content Brief]
[2]. Nayak B P, Minaz N, Pasha K. Molsidomine ameliorates diabetic peripheral neuropathy complications in Wistar rats. Animal Model Exp Med. 2021 Mar 23;4(3):243-248. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.1283 mL | 20.6415 mL | 41.2831 mL | 103.2077 mL |
| 5 mM | 0.8257 mL | 4.1283 mL | 8.2566 mL | 20.6415 mL | |
| 10 mM | 0.4128 mL | 2.0642 mL | 4.1283 mL | 10.3208 mL | |
| 15 mM | 0.2752 mL | 1.3761 mL | 2.7522 mL | 6.8805 mL | |
| 20 mM | 0.2064 mL | 1.0321 mL | 2.0642 mL | 5.1604 mL | |
| 25 mM | 0.1651 mL | 0.8257 mL | 1.6513 mL | 4.1283 mL | |
| 30 mM | 0.1376 mL | 0.6881 mL | 1.3761 mL | 3.4403 mL | |
| 40 mM | 0.1032 mL | 0.5160 mL | 1.0321 mL | 2.5802 mL | |
| 50 mM | 0.0826 mL | 0.4128 mL | 0.8257 mL | 2.0642 mL | |
| 60 mM | 0.0688 mL | 0.3440 mL | 0.6881 mL | 1.7201 mL | |
| 80 mM | 0.0516 mL | 0.2580 mL | 0.5160 mL | 1.2901 mL | |
| 100 mM | 0.0413 mL | 0.2064 mL | 0.4128 mL | 1.0321 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Molsidomine Related Classifications
HY-B1069 Related Classifications
Powered by Bioz